HuGE Literature Finder
Records
1
-
7
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer 2019 Jan . Sharma Manish R, Joshi Smita S, Karrison Theodore G, Allen Kenisha, Suh Grace, Marsh Robert, Kozloff Mark F, Polite Blase N, Catenacci Daniel V T, Kindler Hedy |
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. The oncologist 2017 Feb . Kim Ji-Won, Lee Keun-Wook, Kim Kyu-Pyo, Lee Ju Hyun, Hong Yong Sang, Kim Jeong-Eun, Kim Sun Young, Park Sook Ryun, Nam Byung-Ho, Cho Sang-Hee, Chung Ik-Joo, Park Young Suk, Oh Ho-Suk, Lee Myung-Ah, Kang Hye Jin, Park Young Iee, Song Eun-Kee, Han Hye Sook, Lee Kyu Taeg, Shin Dong Bok, Kang Jung Hun, Zang Dae Young, Kim Jee Hyun, Kim Tae W |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan 2017 02 37 (1): 35-42. Deng Bo, Jia Liqun, Tan Huangying, Lou Yanni, Li Xue, Li Yuan, Yu Li |
FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC research notes 2014 7 (1): 260. Bécouarn Yves, Cany Laurent, Pulido Marina, Beyssac Richard, Texereau Patrick, Le Morvan Valérie, Béchade Dominique, Brunet René, Aitouferoukh Sofiane, Lalet Caroline, Mathoulin-Pélissier Simone, Fonck Marianne, Robert Jacqu |
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. British journal of cancer 2013 Sep 109 (6): 1420-7. Kim S Y, S Hong Y, K Shim E, Kong S-Y, Shin A, Baek J Y, Jung K |
Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 2011 Jul 117 (14): 3156-62. Shulman Katerina, Cohen Ilana, Barnett-Griness Ofra, Kuten Abraham, Gruber Stephen B, Lejbkowicz Flavio, Rennert G |
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. Anticancer research 2011 Jan 31 (1): 359-66. Freyer Gilles, Duret Aude, Milano Gerard, Chatelut Etienne, Rebischung Christine, Delord Jean-Pierre, Merrouche Yacine, Lledo Gerard, Etienne Marie-Christine, Falandry Clai |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 16, 2022
- Content source: